(Reuters) -CVS Health, which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' new HIV prevention drug to its commercial plans for now, a spokesperson told Reuters, despite ...
Two brothers were convicted in Fort Lauderdale federal court of buying up black-market HIV drugs and selling them to unwitting patients and pharmacies, including two in Miami Beach. Liz O. Baylen ...
CVS Health Inc. (NYSE:CVS) said it will not add Gilead Sciences Inc.’s (NASDAQ:GILD) new HIV prevention drug Yeztugo to its commercial plans. In June, the U.S. Food and Drug Administration (FDA) ...
Gilead Sciences Inc.’s shares fell after CVS Health Corp said it hasn’t yet added its new HIV prevention shot to its commercial drug plans. “As is typical with new-to-market products, we undergo a ...
A vial of lenacapavir, the new HIV prevention injectable drug that only needs to be administered twice yearly but provides almost complete protection. (Nardus Engelbrecht | AP) The U.S. announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results